obesityLITE Panel

Obesity is a serious, chronic disease currently affecting a large percent of the global population with numbers affected predicted to rise in future years. To combat this rising healthcare challenge, many pharmaceutical companies are pursuing a strategy of targeting multiple receptors simultaneously for synergistic additive therapeutic benefits while mitigating safety-related concerns. With anti-obesity target combination therapies quickly gaining market interest, Eurofins Discovery LeadHunter^TM Services now includes the obesityLITE panel featuring a focused set of cell-based assays ideal for testing functional activity of desired therapies against multiple disease-relevant targets in one convenient screen.
 
This one-of-a-kind assay panel enables accelerated assessment of potency, selectivity, and mechanism of action characterizations through functional dose response profiling of small and large molecule libraries. obesityLITE includes 25 assays targeting leptin receptor and G-protein-coupled receptors (GPCRs) implicated in metabolic regulation including GLP-1R, GIPR, GCGR, MC4R, CCKAR, amylin, neuropeptide Y, ghrelin, and orexin receptors. The panel offers profiling in GPCR β-arrestin or second messenger assays in agonist or antagonist modes enabling detection of any biased compounds. Eurofins Discovery LeadHunter Services’ robust platform offers the flexibility to create personalized screening solutions by combining panel screen with ad-hoc counterscreen assays from a comprehensive set of GPCR assay services.
 
obesityLITE panel data featured below, using obesity drugs that have been FDA approved or are in clinical development, highlights the effectiveness of this platform in profiling for multi-receptor targeted therapies. This panel validation provides Eurofins Discovery a portal to actively pursue current market trends with therapeutic area-based solutions.
 

Figure 1. obesityLITE panel profiling of FDA approved drugs, single GLP-1R agonist, Semaglutide and dual GLP-1R/GIPR agonist, Tirzepatide, along with a triple GLP-1R/GIPR/GCGR agonist, Retatrutide, currently in clinical development.